CD8A and neoplasm: ZIKV acts on the basis of GSCs, to which it is extremely sensitive, and can inhibit the proliferation of glioma cells by inducing apoptosis of GSCs, break the supporting effect of GSCs on immune escape, and further activate CD8+ T cells to complete the clearance of tumor cells (62).